BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12502798)

  • 1. Functional interaction of nuclear factor y and sp1 is required for activation of the epstein-barr virus C promoter.
    Boreström C; Zetterberg H; Liff K; Rymo L
    J Virol; 2003 Jan; 77(2):821-9. PubMed ID: 12502798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.
    Schlager S; Speck SH; Woisetschläger M
    J Virol; 1996 Jun; 70(6):3561-70. PubMed ID: 8648690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter-proximal regulatory elements involved in oriP-EBNA1-independent and -dependent activation of the Epstein-Barr virus C promoter in B-lymphoid cell lines.
    Nilsson T; Zetterberg H; Wang YC; Rymo L
    J Virol; 2001 Jul; 75(13):5796-811. PubMed ID: 11390581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-cell lines immortalized with an Epstein-Barr virus mutant lacking the Cp EBNA2 enhancer are biased toward utilization of the oriP-proximal EBNA gene promoter Wp1.
    Yoo LI; Mooney M; Puglielli MT; Speck SH
    J Virol; 1997 Dec; 71(12):9134-42. PubMed ID: 9371570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining the role of the Epstein-Barr virus Cp EBNA2-dependent enhancer during the establishment of latency by using mutant and wild-type viruses recovered from cottontop marmoset lymphoblastoid cell lines.
    Yoo L; Speck SH
    J Virol; 2000 Dec; 74(23):11115-20. PubMed ID: 11070007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines.
    Puglielli MT; Woisetschlaeger M; Speck SH
    J Virol; 1996 Sep; 70(9):5758-68. PubMed ID: 8709191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation of transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides with promoter down-regulation during virus-induced B-cell transformation.
    Tierney RJ; Kirby HE; Nagra JK; Desmond J; Bell AI; Rickinson AB
    J Virol; 2000 Nov; 74(22):10468-79. PubMed ID: 11044091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Epstein-Barr virus BamHI C promoter is not essential for B cell immortalization in vitro, but it greatly enhances B cell growth transformation.
    Tierney RJ; Nagra J; Rowe M; Bell AI; Rickinson AB
    J Virol; 2015 Mar; 89(5):2483-93. PubMed ID: 25540367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral and cellular factors influence the activity of the Epstein-Barr virus BCR2 and BWR1 promoters in cells of different phenotype.
    Nilsson T; Sjöblom A; Masucci MG; Rymo L
    Virology; 1993 Apr; 193(2):774-85. PubMed ID: 8384755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of Epstein-Barr virus regulatory sequences upstream of the EBNA gene promoter Wp1 is unfavorable for B-Cell immortalization.
    Yoo LI; Woloszynek J; Templeton S; Speck SH
    J Virol; 2002 Nov; 76(22):11763-9. PubMed ID: 12388739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines.
    Hutchings IA; Tierney RJ; Kelly GL; Stylianou J; Rickinson AB; Bell AI
    J Virol; 2006 Nov; 80(21):10700-11. PubMed ID: 16920819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites.
    Lok CN; Lang AJ; Mirski SE; Cole SP
    Biochem J; 2002 Dec; 368(Pt 3):741-51. PubMed ID: 12197834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of transcripts initiated from two viral promoters (Cp and Wp) in Epstein-Barr virus-infected nasopharyngeal carcinoma cells and biopsies.
    Chang Y; Sheen TS; Lu J; Huang YT; Chen JY; Yang CS; Tsai CH
    Lab Invest; 1998 Jun; 78(6):715-26. PubMed ID: 9645762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the CBF2 binding site within the Epstein-Barr virus latency C promoter and its role in modulating EBNA2-mediated transactivation.
    Fuentes-Pananá EM; Ling PD
    J Virol; 1998 Jan; 72(1):693-700. PubMed ID: 9420275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variable methylation of the Epstein-Barr virus Wp EBNA gene promoter in B-lymphoblastoid cell lines.
    Elliott J; Goodhew EB; Krug LT; Shakhnovsky N; Yoo L; Speck SH
    J Virol; 2004 Dec; 78(24):14062-5. PubMed ID: 15564516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection.
    Woisetschlaeger M; Jin XW; Yandava CN; Furmanski LA; Strominger JL; Speck SH
    Proc Natl Acad Sci U S A; 1991 May; 88(9):3942-6. PubMed ID: 1850841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation of the EBV genome and establishment of restricted latency in low-passage EBV-infected 293 epithelial cells.
    Paulson EJ; Fingeroth JD; Yates JL; Speck SH
    Virology; 2002 Jul; 299(1):109-21. PubMed ID: 12167346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of EBNA gene transcription in lymphoblastoid cell lines: characterization of sequences downstream of BCR2 (Cp).
    Puglielli MT; Desai N; Speck SH
    J Virol; 1997 Jan; 71(1):120-8. PubMed ID: 8985330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple EBNA1-binding sites within oriPI are required for EBNA1-dependent transactivation of the Epstein-Barr virus C promoter.
    Zetterberg H; Boreström C; Nilsson T; Rymo L
    Int J Oncol; 2004 Sep; 25(3):693-6. PubMed ID: 15289871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latency pattern of Epstein-Barr virus and methylation status in Epstein-Barr virus-associated hemophagocytic syndrome.
    Yoshioka M; Kikuta H; Ishiguro N; Endo R; Kobayashi K
    J Med Virol; 2003 Jul; 70(3):410-9. PubMed ID: 12767005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.